606143-68-4 Usage
Chemical structure
The compound has a complex structure, consisting of an oxadiazole ring and a benzimidazole ring.
Oxadiazole ring
A five-membered ring with two nitrogen atoms and one oxygen atom.
Benzimidazole ring
A six-membered ring with one nitrogen atom fused to a five-membered imidazole ring.
Chloro group
A chlorine atom (-Cl) attached to the benzene ring.
Methyl group
A methyl group (-CH3) attached to the benzene ring.
Fluoro group
A fluorine atom (-F) attached to the benzimidazole ring.
Amino group
An amino group (-NH2) attached to the benzene ring.
Potential pharmacological properties
The compound may have potential pharmacological properties due to its structural features.
Further research
Further research may be needed to understand the compound's potential applications and effects.
Molecular weight
The molecular weight of the compound is approximately 369.76 g/mol.
Appearance
The appearance of the compound is not specified in the provided material, but it is likely a solid due to its molecular weight and complexity.
Solubility
The solubility of the compound is not specified in the provided material, but it may be soluble in organic solvents such as dimethyl sulfoxide (DMSO) or methanol.
Stability
The stability of the compound is not specified in the provided material, but it may be sensitive to light, heat, or moisture due to its complex structure and functional groups.
Check Digit Verification of cas no
The CAS Registry Mumber 606143-68-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,0,6,1,4 and 3 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 606143-68:
(8*6)+(7*0)+(6*6)+(5*1)+(4*4)+(3*3)+(2*6)+(1*8)=134
134 % 10 = 4
So 606143-68-4 is a valid CAS Registry Number.
606143-68-4Relevant academic research and scientific papers
N3 alkylated benzimidazole derivatives as MEK inhibitors
-
Page 12; 54, (2008/06/13)
Disclosed are compounds of the formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein W, R1, R2, R7, R8, R9 and R10 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
